Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2023 | 12-2022 | |
| Operating Expenses | 11,445 | 0 |
| Operating Income | -11,445 | N/A |
| Interest Expense | 44 | 0 |
| Other Income | 346 | 0 |
| Pre-tax Income | -11,143 | 0 |
| Net Income Continuous | -11,143 | N/A |
| Net Income | $-11,143 | $N/A |
| EPS Basic Total Ops | -12.10 | N/A |
| EPS Basic Continuous Ops | -12.10 | N/A |
| EPS Diluted Total Ops | -12.10 | N/A |
| EPS Diluted Continuous Ops | -12.10 | N/A |
| EBITDA(a) | $-11,051 | $N/A |